testosteron depo 250 mg/1 ml rastvor za injekciju
galenika d.o.o. - testosteron - rastvor za injekciju - 250 mg/1 ml - 1 ml rastvora za injekciju sadrži: 250 mg testosteron enantata
testosteron depo 250 mg/1 ml rastvor za injekciju
galenika d.o.o. - testosteron - rastvor za injekciju - 250 mg/1 ml - 1 ml rastvora za injekciju sadrži: 250 mg testosteron enantata
androgel 50 mg transdermalni gel u vrećici
besins healthcare s.a., rue washington 80, ixelles, belgija - testosteron - transdermalni gel u vrećici - 50 mg - urbroj: jedna vrećica (5 g gela) sadrži 50 mg testosterona
testarzon 20 mg/g transdermalni gel
the simple pharma company limited, ground floor, 71 lower baggot st, dublin, irska - testosteron - transdermalni gel - 20 mg/g - urbroj: jedan gram gela sadrži 20 mg testosterona jedan potisak na pumpici istiskuje 1,15 g (1,25 ml) gela što odgovara 23 mg testosterona
nebido 1000 mg/4 ml otopina za injekciju
bayer d.o.o., radnička cesta 80, zagreb, hrvatska - testosterondekanoat - otopina za injekciju - 1000 mg/4 ml - urbroj: 1 ml otopine za injekciju sadrži 250 mg testosteron undekanoata što odgovara 157,9 mg testosterona
firmagon
ferring pharmaceuticals a/s - degarelix - prostatske neoplazme - endokrinska terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostatske neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostatske neoplazme - endokrinska terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
orgovyx
accord healthcare s.l.u. - relugolix - prostatske neoplazme - endokrinska terapija - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
zytiga
janssen-cilag international n.v. - abirateron acetat - prostatske neoplazme - endokrinska terapija - zytiga je navedena s преднизоном ili преднизолоном za liječenje метастатического kastracija otporan raka prostate kod odraslih muškaraca asimptomatska ili slabo simptomi nakon neuspjeha androgen-депривационной terapije kod kojih je kemoterapija nije klinički indicatedthe obrade metastatic кастраци-aksijalni rak prostate kod odraslih muškaraca, čija je bolest napredovala nakon kemoterapije na temelju доцетаксела način.